Published in N Engl J Med on December 20, 1990
Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils. J Exp Med (1998) 1.75
Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci U S A (2004) 1.30
Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med (2001) 1.25
GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A (2009) 1.14
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev (2012) 1.03
Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol (2012) 1.02
The catalytic architecture of leukotriene C4 synthase with two arginine residues. J Biol Chem (2011) 0.99
Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc Natl Acad Sci U S A (2001) 0.96
Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity. J Exp Med (1994) 0.94
Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet (1995) 0.92
Recent advances in asthma. Postgrad Med J (1992) 0.92
In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokinet (1995) 0.92
Attenuation of exercise induced asthma by local hyperthermia. Thorax (1992) 0.91
The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet (1995) 0.88
Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax (1993) 0.88
Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise. Br J Sports Med (2005) 0.87
Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol (1992) 0.87
Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br J Pharmacol (1992) 0.86
Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet (1995) 0.86
Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits. Br J Pharmacol (1992) 0.85
Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax (1994) 0.85
Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet (1995) 0.83
Reduction in leukotriene B4 generation by bronchoalveolar lavage cells in asthma. Thorax (1995) 0.82
Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma. Thorax (2002) 0.81
Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air. Thorax (1997) 0.79
The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet (1995) 0.79
Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males. J Clin Invest (2017) 0.79
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers. Clin Pharmacokinet (1995) 0.78
The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Eur J Clin Pharmacol (2017) 0.78
Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Clin Pharmacokinet (1995) 0.78
Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation. Thorax (1995) 0.77
Leukotriene receptor antagonists: clinical effects. J R Soc Med (1997) 0.76
Asthma control in adolescents: role of leukotriene inhibitors. Adolesc Health Med Ther (2010) 0.75
Development and validation of a liquid chromatography-mass spectrometry method for the determination of zileuton in human plasma. Sci Pharm (2014) 0.75
Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Br J Clin Pharmacol (1991) 0.75
Leukotrienes and aspirin induced asthma. Thorax (1993) 0.75
'Indirect' challenges from science to clinical practice. Eur Clin Respir J (2016) 0.75
Antileukotrienes, asthma pathogenesis and the pharmaceutical industry. CMAJ (1999) 0.75
Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma. Respir Med (2010) 0.75
Leukotrienes in asthma and allergic rhinitis. N Engl J Med (1990) 0.75
Clinical management of asthma in the 1990s. Current therapy and new directions. Drugs (1996) 0.75
The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. Clin Pharmacokinet (1995) 0.75
The effect of food on the pharmacokinetics of zileuton. Clin Pharmacokinet (1995) 0.75
Let-7 microRNA-dependent control of leukotriene signaling regulates the transition of hematopoietic niche in mice. Nat Commun (2017) 0.75
Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Clin Pharmacokinet (1995) 0.75
Regulatory sequences involved in the promotion and termination of RNA transcription. Annu Rev Genet (1979) 54.83
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
A system to study promoter and terminator signals recognized by Escherichia coli RNA polymerase. Gene Amplif Anal (1981) 8.21
Sponsorship, authorship, and accountability. Lancet (2001) 7.10
Sponsorship, authorship, and accountability. N Engl J Med (2001) 6.20
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Sponsorship, authorship and accountability. CMAJ (2001) 5.86
Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science (2001) 5.40
The relationship between function and DNA sequence in an intercistronic regulatory region in phage lambda. Nature (1978) 5.38
Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. Nat Genet (1995) 5.02
Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature (1990) 4.81
The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature (1984) 4.61
Purified lambda regulatory protein cII positively activates promoters for lysogenic development. Nature (1981) 4.60
Termination of transcription in E. coli. Cell (1983) 4.42
Efficient expression of Escherichia coli galactokinase gene in mammalian cells. Proc Natl Acad Sci U S A (1982) 4.25
Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem (1992) 4.22
Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med (1977) 4.14
Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure. Nature (1979) 4.11
Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol (2000) 4.10
Guideline for the management of breast lumps. Can J Surg (1998) 4.02
The use of pKc30 and its derivatives for controlled expression of genes. Methods Enzymol (1983) 3.90
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys (1995) 3.86
Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 3.84
Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med (1998) 3.83
Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell (1984) 3.81
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Termination of transcription in bacteriophage lambda. Heterogeneous, 3'-terminal oligo-adenylate additions and the effects of rho factor. J Biol Chem (1975) 3.71
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys (2001) 3.70
Surveillance and prevention of residential-fire injuries. N Engl J Med (1996) 3.60
Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA (1998) 3.57
Translational coupling at an intercistronic boundary of the Escherichia coli galactose operon. Cell (1982) 3.56
Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci U S A (1989) 3.55
A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol Microbiol (2000) 3.50
Distinction awards and racial discrimination. BMJ (1998) 3.33
Highly reiterated sequences of SIMIANSIMIANSIMIANSIMIANSIMIAN. Science (1978) 3.29
Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol (1994) 3.27
Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology (1984) 3.27
Expression and characterization of the human c-myc DNA-binding protein. Mol Cell Biol (1985) 3.24
Constitutive function of a positively regulated promoter reveals new sequences essential for activity. J Biol Chem (1987) 3.23
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 3.21
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Role of adherence in growth of Acinetobacter calcoaceticus RAG-1 on hexadecane. J Bacteriol (1981) 2.96
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
The origin of the chemiluminescence of phagocytosing granulocytes. J Clin Invest (1976) 2.92
Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol (1981) 2.92
gridlock, an HLH gene required for assembly of the aorta in zebrafish. Science (2000) 2.90
The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med (1994) 2.90
Nucleotide sequence homology at the 3' termini of RNA from vesicular stomatitis virus and its defective interfering particles. Proc Natl Acad Sci U S A (1978) 2.82
Sequence of Cro gene of bacteriophage lambda. Nature (1977) 2.78
Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proc Natl Acad Sci U S A (1984) 2.74
Adherence of Acinetobacter calcoaceticus RAG-1 to human epithelial cells and to hexadecane. Infect Immun (1981) 2.74
Bacterial adherence to polystyrene: a replica method of screening for bacterial hydrophobicity. Appl Environ Microbiol (1981) 2.73
E1A 13S and 12S mRNA products made in Escherichia coli both function as nucleus-localized transcription activators but do not directly bind DNA. Mol Cell Biol (1985) 2.68
Sponsorship, authorship, and accountability. Ann Intern Med (2001) 2.66
Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol (1985) (1988) 2.64
Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A (1993) 2.64
Endocytosis in Chang liver cells. Quantitation by sucrose- 3 H uptake and inhibition by cytochalasin B. J Cell Biol (1971) 2.63
A rho-dependent termination site in the gene coding for tyrosine tRNA su3 of Escherichia coli. Nature (1978) 2.58
Affecting gene expression by altering the length and sequence of the 5' leader. Proc Natl Acad Sci U S A (1984) 2.58
Nucleotide sequence of the operator-promoter region of the galactose operon of Escherichia coli. Proc Natl Acad Sci U S A (1977) 2.57
Microinjected c-myc as a competence factor. Science (1985) 2.56
Evolution of two-component signal transduction. Mol Biol Evol (2000) 2.55
Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc Natl Acad Sci U S A (1991) 2.54
Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med (1993) 2.53
A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med (2001) 2.50
Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J Bacteriol (2000) 2.50
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A (1994) 2.41
Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol (1987) 2.41
Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest (1987) 2.40
Adenovirus E1a gene product expressed at high levels in Escherichia coli is functional. Science (1984) 2.38
Structure and function of the cy control region of bacteriophage lambda. J Mol Biol (1980) 2.37
A promoter of pBR322 activated by cAMP receptor protein. Nucleic Acids Res (1981) 2.37
Active anaphylaxis in IgE-deficient mice. Nature (1994) 2.32
Respiratory syncytial virus. Brief review. Arch Virol (1985) 2.31
Pentapeptide nuclear localization signal in adenovirus E1a. Mol Cell Biol (1987) 2.30
Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res (1997) 2.30
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med (1994) 2.23
Promoter for the establishment of repressor synthesis in bacteriophage lambda. Proc Natl Acad Sci U S A (1980) 2.23
Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 2.20
Efficient expression of influenza virus NS1 nonstructural proteins in Escherichia coli. Proc Natl Acad Sci U S A (1983) 2.19
Novel, ligation-dependent PCR assay for detection of hepatitis C in serum. J Clin Microbiol (1996) 2.19
The Republican and Democratic candidates speak on health care. N Engl J Med (2000) 2.18
Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest (1974) 2.16
The composition and the structure of bacterioferritin of Escherichia coli. Biochem J (1981) 2.15
Respiratory syncytial virus infection in mice. Infect Immun (1984) 2.14
Removal of a terminator structure by RNA processing regulates int gene expression. J Mol Biol (1984) 2.13
Bacteriophage lambda protein cII binds promoters on the opposite face of the DNA helix from RNA polymerase. Nature (1983) 2.13
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax (2000) 2.10
Nucleotide sequences of the 5' and 3' termini of bacteriophage T7 early messenger RNAs synthesized in vivo: evidence for sequence specificity in RNA processing. J Mol Biol (1974) 2.10
Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J Biol Chem (1994) 2.04
What more do we have to do? Br Dent J (1992) 2.04